Skip to content
value.today

Cipla Limited vs Dr. Reddy's Laboratories Limited

Add a company

Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.

In short

  • Cipla Limited and Dr. Reddy's Laboratories Limited are worth about the same: $12.3 B and $12.5 B (market caps of Nov 19, 2026).
  • Dr. Reddy's Laboratories Limited had more revenue: $3.6 B against $3.0 B for Cipla Limited, both in the year to March 2026.
  • Dr. Reddy's Laboratories Limited earned more: net income of $463 M against $419 M for Cipla Limited.
  • Cipla Limited keeps more of each dollar of sales: a net margin of 14.0% against 12.8% for Dr. Reddy's Laboratories Limited.
  • Dr. Reddy's Laboratories Limited employs more people: 24,795 against 23,000 at Cipla Limited. Each employee brings in about $130,097 of revenue at Cipla Limited and $146,292 at Dr. Reddy's Laboratories Limited.
  • On price to earnings, Cipla Limited trades at 29.3× and Dr. Reddy's Laboratories Limited at 27.1×: investors pay more for each dollar of Cipla Limited's profit.

Market value, the same start = 100

From Jan 2020: how each one's value moved, whatever its size.

0581171752342020202120222023202420252026Cipla Limited 230Dr. Reddy's Laboratories Limited 188

Revenue by fiscal year

US$ billions, as reported in each year's annual results.

$0B$1B$2B$3B$4B201620172018201920202021202220232024Dr. Reddy's Laboratories Limited $4B

Side by side

Side-by-side comparison; ▲ marks the best value of a measure where higher or lower is better
MeasureCipla Limited
CIPLA.BO · #1,872 in the world
Dr. Reddy's Laboratories Limited
DRREDDY.BO · #1,834 in the world
Profile
Country🇮🇳 India🇮🇳 India
SectorHealthcareHealthcare
IndustryPharmaceuticalPharmaceutical
Founded19351984
Size
Market cap$12.3 B$12.5 B
Revenue$3.0 B$3.6 B
Net income$419 M$463 M▲ best
Employees23,00024,795
Valuation
P/E ratio29.3×27.1×
Price to sales4.1×3.5×
Price to book3.3×3.0×
Free cash flow yield—1.8%
Profitability
Gross margin—58.5%
Operating margin—22.1%
Net margin—17.4%
Return on equity—18.4%
Return on invested capital—17.7%
Growth
Revenue growth—14.2%
Revenue growth, 3 years a year—10.2%
Earnings per share growth—-0.6%
Financial strength
Debt to equity—0.0×
Net debt to EBITDA—-0.1×
Interest cover—25.4×
Cash
Free cash flow margin—5.8%
Shareholder returns
Dividend yield—0.6%
Shareholder yield—0.8%
Strength scores
Piotroski F-score—2 of 9
Altman Z-score zone—safe
Data as ofMarket cap Nov 2026Market cap Nov 2026; ratios FY2024

▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither

Questions and answers#

Which is bigger, Cipla Limited or Dr. Reddy's Laboratories Limited?

Cipla Limited and Dr. Reddy's Laboratories Limited are worth about the same: $12.3 B and $12.5 B (market caps of Nov 19, 2026).

Which makes more money, Cipla Limited or Dr. Reddy's Laboratories Limited?

Dr. Reddy's Laboratories Limited had more revenue: $3.6 B against $3.0 B for Cipla Limited, both in the year to March 2026. Dr. Reddy's Laboratories Limited earned more: net income of $463 M against $419 M for Cipla Limited.

Which is more profitable, Cipla Limited or Dr. Reddy's Laboratories Limited?

Cipla Limited keeps more of each dollar of sales: a net margin of 14.0% against 12.8% for Dr. Reddy's Laboratories Limited.

Which has more employees, Cipla Limited or Dr. Reddy's Laboratories Limited?

Dr. Reddy's Laboratories Limited employs more people: 24,795 against 23,000 at Cipla Limited. Each employee brings in about $130,097 of revenue at Cipla Limited and $146,292 at Dr. Reddy's Laboratories Limited.

Is Cipla Limited cheaper than Dr. Reddy's Laboratories Limited?

On price to earnings, Cipla Limited trades at 29.3× and Dr. Reddy's Laboratories Limited at 27.1×: investors pay more for each dollar of Cipla Limited's profit. A lower multiple is not by itself a better buy: it also reflects expected growth, risk and accounting.

Sources#

Every figure on this page comes from these, with the date shown next to it.